<DOC>
	<DOCNO>NCT02024555</DOCNO>
	<brief_summary>The primary purpose study investigate efficacy safety oral antimycobacterial therapy patient confirm progressive pulmonary sarcoidosis . We suspect CLEAR regimen improve absolute FVC percent predict chronic pulmonary sarcoidosis participant .</brief_summary>
	<brief_title>Phase II Investigation Antimycobacterial Therapy Progressive , Pulmonary Sarcoidosis</brief_title>
	<detailed_description>Primary Objective : To assess efficacy safety oral CLEAR therapy patient confirm progressive pulmonary sarcoidosis . Hypothesis : The CLEAR regimen improve absolute FVC percent predict chronic pulmonary sarcoidosis participant augment T cell response normalization p56Lck expression IL-2 production .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>Patients sarcoidosis define ATS/ERS/WASOG statement sarcoidosis define clinical presentation consistent sarcoidosis , well biopsy demonstrate granuloma , alternative cause granuloma , tuberculosis least one year prior randomization . Tuberculosis must rule negative histology culture . Diagnosis pulmonary sarcoidosis make least 1 year prior consent date . Evidence disease progression define least two follow four criterion : 1 . Decline absolute percent predict FVC ( FVC &gt; 45 % &lt; =90 % predict value ) DLCO least 5 % serial measurement ( DLCO range &gt; 35 % , measure ) ; 2 . Radiographic progression chest image side side comparison ; 3 . Change dyspnea score , measure Transition Dyspnea Index ( TDI ) ; 4 . Progression pulmonary sarcoidosis necessitate increase antisarcoidosis therapy . Positive peripheral immune response ESAT6 biomarker response CLEAR regimen . Possess evidence parenchymal nodal disease chest radiograph . • Inability obtain consent Age le 18 year age If female , participant either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , use one follow method birth control duration study 90 day study completion : condom , sponge , foam , jelly , diaphragm , intrauterine device vasectomize sole partner . Note : Oral contraceptive pill effective birth control take rifampin rifabutin . Females childbearing potential must negative urine pregnancy test screen visit Endstage fibrotic pulmonary disease Significant underlying liver disease Poor venous access obtain blood sample History active tuberculosis , close contact person active tuberculosis within 6 month prior screen visit positive PPD . Significant disorder , sarcoidosis , would complicate treatment evaluation , respiratory , cardiac , neurologic , musculoskeletal seizure disorder Use investigational drug within 30 day prior screen within 5 halflives agent , whichever longer . Currently receive &gt; 40mg prednisone . ALT AST ≥5 time upper limit normal ( ULN ) Leukopenia , define WBC &lt; 3.0 cells/mm3 absolute neutrophil count &lt; 1000 mm3 Breast feeding . Color perception impairment define inability differentiate color per personal history history optic neuritis cause , include sarcoidosis . Family personal history long QT interval Most recent nuclear medicine scan echocardiogram ( do ) , demonstrate cardiac ejection fraction &lt; 35 % If patient immunomodulators , must regimen ≥3month period stable dose ≥ 4 week . Participant persistent active infection require hospitalization treatment IV antibiotic , IV antiretrovirals , IV antifungal within 30 day baseline , OR oral antibiotic , antiviral , antifungal purpose treat infection , within 14 day baseline . Minocycline doxycycline consider antibiotic use treat sarcoidosis . Any significant finding patient 's medical history physical psychiatric exam prior randomization , opinion investigator , would affect patient safety compliance ability deliver study drug accord protocol . On medication interacts antibiotic CLEAR regimen ( Listed Appendix A ) History receive treatment pulmonary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>